Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Gunzburg, Germany Clinical Trials

A listing of Gunzburg, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (4) clinical trials

Study for the Improvement of Long-Term Outcome Prediction in Patients in Coma After Cardiac Arrest

HOPE conducts a 2.5-year multicenter prospective cohort study in Germany on outcome prediction in the early stages of coma caused by cerebral hypoxia-ischemia. The main features of the project are: Control for a self-fulfilling prophecy Long-term follow-up (12 months) covering acute and neurorehabilitation phases Use of sensitive measures of level ...

Phase N/A

5.28 miles

Learn More »

A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis Axial Spondyloarthritis Psoriatic Arthritis Or Plaque Psoriasis.

The purpose of this non-interventional study is to evaluate the efficacy of etanercept during routine clinical use over a maximum of 12 months in patients with rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, or plaque psoriasis. In so doing, particular attention will be paid to the proportion of those patients who ...

Phase N/A

7.74 miles

Learn More »

A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 12 Years and Older With Moderate to Severe Plaque Psoriasis

The purpose of this study is to monitor the long-term safety of ustekinumab in pediatric participants (aged greater than or equal to 12 years to less than 18 years inclusive) with moderate to severe plaque psoriasis, through monitoring for the following adverse events potentially related to immune modulation: serious infections, ...

Phase N/A

7.74 miles

Learn More »

Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors

This prospective, post marketing, observational, Noninterventional Study (NIS) is designed to compare drug persistence in patients treated with Certolizumab Pegol (CZP) and patients treated with any other subcutaneously (sc) administered Tumor Necrosis Factor (TNF) inhibitor.

Phase N/A

7.74 miles

Learn More »